For the quarter ending 2025-09-30, SKYE has $41,324,289 in assets. $8,488,104 in debts. $18,441,079 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 18,441,079 | 23,838,244 | ||
| Short-term investments | 16,871,229 | 24,747,039 | ||
| Prepaid expenses | 3,712,311 | 1,263,812 | ||
| Other current assets | 900,175 | 733,423 | ||
| Total current assets | 39,924,794 | 50,582,518 | ||
| Property and equipment, net | 1,033,965 | 1,169,056 | ||
| Operating lease right-of-use asset | 311,620 | 355,427 | ||
| Other assets | 53,910 | 53,910 | ||
| Total assets | 41,324,289 | 52,160,911 | ||
| Accounts payable | 2,825,005 | 3,222,510 | ||
| Accrued payroll liabilities | 920,774 | 868,024 | ||
| Other current liabilities | 2,366,123 | 2,220,063 | ||
| Estimate for accrued legal contingencies and related expenses | 2,054,357 | 1,806,065 | ||
| Operating lease liability, current portion | 201,638 | 195,046 | ||
| Total current liabilities | 8,367,897 | 8,311,708 | ||
| Operating lease liability, net of current portion | 120,207 | 172,494 | ||
| Total liabilities | 8,488,104 | 8,484,202 | ||
| Common stock, 0.001 par value 100,000,000 shares authorized at september30, 2025 and december31, 2024 30,989,046 and 30,974,559 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 30,989 | 30,988 | ||
| Additional paid-in-capital | 205,237,719 | 203,323,584 | ||
| Accumulated deficit | -172,432,523 | -159,677,863 | ||
| Total stockholders equity | 32,836,185 | 43,676,709 | ||
| Total liabilities and stockholders equity | 41,324,289 | 52,160,911 | ||
Skye Bioscience, Inc. (SKYE)
Skye Bioscience, Inc. (SKYE)